| 001 | 1053910 | ||
| 005 | 20260201202253.0 | ||
| 024 | 7 | _ | |a 10.1093/neuonc/noaf201.1161 |2 doi |
| 024 | 7 | _ | |a 1522-8517 |2 ISSN |
| 024 | 7 | _ | |a 1523-5866 |2 ISSN |
| 037 | _ | _ | |a FZJ-2026-01608 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Mair, Maximilian J |0 P:(DE-HGF)0 |b 0 |
| 111 | 2 | _ | |a 7th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies |g SNO / WFNOS 2025 |c Honolulu |d 2025-11-20 - 2025-11-23 |w USA |
| 245 | _ | _ | |a IMG-82. Positron emission tomography (PET) use among European Organisation for Research and Treatment of Cancer – Brain Tumour Group (EORTC-BTG) sites – a cross-sectional survey |
| 260 | _ | _ | |c 2025 |
| 336 | 7 | _ | |a Abstract |b abstract |m abstract |0 PUB:(DE-HGF)1 |s 1769939581_17710 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a Conference Paper |0 33 |2 EndNote |
| 336 | 7 | _ | |a INPROCEEDINGS |2 BibTeX |
| 336 | 7 | _ | |a conferenceObject |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Conference Abstract |2 DataCite |
| 336 | 7 | _ | |a OTHER |2 ORCID |
| 520 | _ | _ | |a AbstractBACKGROUNDPositron emission tomography (PET) is increasingly used in patients with brain tumors, yet its adoption varies across institutions.METHODSTo assess the current landscape, a cross-sectional survey was conducted among European Organization for Research and Treatment of Cancer (EORTC) – Brain Tumour Group (BTG) sites between June 2024 and August 2024.RESULTSOut of the 312 sites invited, 103 replies from 20 countries in the Europe/Middle East region were received. PET availability was reported by 96/103 (93.2%) sites, of whom 74 reported PET use in patients with brain tumors. Most frequently, PET was performed in glioma (69/74, 93.2%), followed by brain metastasis (58/74, 78.4%), meningioma (52/74, 70.3%), and CNS lymphoma (46/74, 62.2%). Amino acid PET was used at 62/71 centers (87.3%), mainly in glioma (58/59, 98.3%) and for differentiation of tumor progression from treatment-related changes (58/59, 98.3%), differential diagnosis (54/59, 91.5%), and hotspot delineation (47/59, 79.7%). Somatostatin receptor (SSTR) PET was performed at 50/68 sites (73.5%), predominantly in meningioma (48/49, 98.0%), and for patient selection before radioligand therapy (41/49, 83.7%) as well as for target volume definition in radiotherapy (33/49, 67.3%) and differential diagnosis (27/49, 55.1%). PET was covered by statutory health insurance at 46/59 (78.0%) centers for amino acid PET and 33/49 (67.3%) for SSTR PET according to self-reported information. Main reasons for not performing PET in clinical routine included limited availability of tracers (14/29, 48.3%), high cost (11/29, 37.9%), and PET considered unnecessary by referring physicians (8/29, 27.6%).CONCLUSIONPET is widely used among EORTC-BTG sites, although implementation varies and is influenced by factors such as tracer availability, cost, and institutional perceptions. While further data from broader surveys including non-academic institutions is needed, the findings support the implementation of PET as clinical trial endpoint. |
| 536 | _ | _ | |a 5253 - Neuroimaging (POF4-525) |0 G:(DE-HGF)POF4-5253 |c POF4-525 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Lohmann, Philipp |0 P:(DE-Juel1)145110 |b 1 |u fzj |
| 700 | 1 | _ | |a Galldiks, Norbert |0 P:(DE-Juel1)143792 |b 2 |
| 700 | 1 | _ | |a Belting, Mattias |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Brandal, Petter |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Broen, Martinus P G |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Cicone, Francesco |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Daisne, Jean-François |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Ducray, François |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Ehret, Felix |0 P:(DE-HGF)0 |b 9 |
| 700 | 1 | _ | |a Furtner, Julia |0 P:(DE-HGF)0 |b 10 |
| 700 | 1 | _ | |a Jakola, Asgeir S |0 P:(DE-HGF)0 |b 11 |
| 700 | 1 | _ | |a Niyazi, Maximilian |0 P:(DE-HGF)0 |b 12 |
| 700 | 1 | _ | |a Pellerino, Alessia |0 P:(DE-HGF)0 |b 13 |
| 700 | 1 | _ | |a Rasschaert, Marika |0 P:(DE-HGF)0 |b 14 |
| 700 | 1 | _ | |a Razis, Evangelia |0 P:(DE-HGF)0 |b 15 |
| 700 | 1 | _ | |a Sahm, Felix |0 P:(DE-HGF)0 |b 16 |
| 700 | 1 | _ | |a Smits, Marion |0 P:(DE-HGF)0 |b 17 |
| 700 | 1 | _ | |a Tolboom, Nelleke |0 P:(DE-HGF)0 |b 18 |
| 700 | 1 | _ | |a Verger, Antoine |0 P:(DE-HGF)0 |b 19 |
| 700 | 1 | _ | |a Le Rhun, Emilie |0 P:(DE-HGF)0 |b 20 |
| 700 | 1 | _ | |a Minniti, Giuseppe |0 P:(DE-HGF)0 |b 21 |
| 700 | 1 | _ | |a Weller, Michael |0 P:(DE-HGF)0 |b 22 |
| 700 | 1 | _ | |a Preusser, Matthias |0 P:(DE-HGF)0 |b 23 |
| 700 | 1 | _ | |a Albert, Nathalie L |0 P:(DE-HGF)0 |b 24 |
| 773 | _ | _ | |a 10.1093/neuonc/noaf201.1161 |0 PERI:(DE-600)2094060-9 |y 2025 |g Vol. 27, no. Supplement_5, p. v292 - v293 |x 1523-5866 |
| 856 | 4 | _ | |u https://academic.oup.com/neuro-oncology/article/27/Supplement_5/v292/8319344 |
| 909 | C | O | |o oai:juser.fz-juelich.de:1053910 |p VDB |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 1 |6 P:(DE-Juel1)145110 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 2 |6 P:(DE-Juel1)143792 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5253 |x 0 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2024-12-11 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEURO-ONCOLOGY : 2022 |d 2024-12-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-11 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-11 |
| 915 | _ | _ | |a IF >= 15 |0 StatID:(DE-HGF)9915 |2 StatID |b NEURO-ONCOLOGY : 2022 |d 2024-12-11 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-4-20090406 |k INM-4 |l Physik der Medizinischen Bildgebung |x 0 |
| 980 | _ | _ | |a abstract |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-Juel1)INM-4-20090406 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
Gast ::